Xuanzhu Biopharmaceutical, an innovative drug research and development subsidiary of Hong Kong-listed Sihuan Pharmaceutical Holdings Group, has completed an 800-million-yuan ($116 million) Series A round of equity financing led by Chinese state-owned investment firm State Development and Investment Corporation (SDIC).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
